Chemistry & Biodiversity · 2020 · 25 citations · 14 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryLead Compound DesignOncology PharmacologyStructure-activity Relationship AnalysisAnticancer ActivityAnticancer Compound ScreeningAnticancer Natural ProductsAntiproliferative AgentsAntiproliferative Drug ActionAssayChemical Structure-activity RelationshipsMedicinal Chemistry Applications
Abstract In order to find novel antitumor candidate agents with high efficiency and low toxicity, 14 novel substituted 5‐anilino‐ α ‐glucofuranose derivatives have been designed, synthesized and evaluated for antiproliferative activities in vitro. Their structures were characterized by NMR ( 1 H and 13 C) and HR‐MS, and configuration ( R / S ) at C(5) was identified by two‐dimensional 1 H, 1 H‐NOESY‐NMR spectrum. Their antiproliferative activities against human tumor cells were investigated by MTT assay. The results demonstrated that most of the synthesized compounds had antiproliferative effects comparable to the reference drugs gefitinib and lapatinib. In particular, (5 R )‐5‐ O ‐(3‐chloro‐4‐{[5‐(4‐fluorophenyl)thiophen‐2‐yl]methyl}anilino)‐5‐deoxy‐1,2‐ O ‐(1‐methylethylidene)‐ α ‐glucofuranose ( 9da ) showed the most potent antiproliferative effects against SW480, A431 and A549 cells, with IC 50 values of 8.57, 5.15 and 15.24 μ m , respectively. This work suggested 5‐anilino‐ α ‐glucofuranose as an antitumor core structure that may open a new way to develop more potent anti‐cancer agents.
14
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia, Cai‐Hong Yun, Eunyoung Park et al. · Nature · 2016 · 879 citations · Full text
Medicine, Oncology, Pharmacology +11
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara et al. · The Oncologist · 2003 · 577 citations · Full text